More Than 100 Applications Lost Equivalence Rating Thanks To Allegedly Falsified Data At Two CROs
Executive Summary
Sponsors must decide whether to repeat bioequivalence and other studies after two CROs were found to have potentially falsified data, causing the US FDA to reject all data produced by the firms.
You may also be interested in...
Clinical Data Integrity: Clean US FDA Inspection No Guarantee That DoJ Won’t Investigate
Justice department has investigative tools that can uncover fraudulent activity even when a clinical site passes inspection, DoJ’s Clint Narver says; in deciding whether to self-report possible clinical trial fraud to FDA and DoJ, sponsors should consider that other companies would benefit from knowing this information about a particular site or investigator.
Strides Founder Back As MD, Asserts Confidence In US As Company Exits Parts Of Europe
Back as Strides managing director, founder Arun Kumar is confident of reversing a slide in profits via a recalibration strategy that saw the company exit Canada and a few European markets. Meanwhile, eyes are on the fallout of a CRO that serviced Strides apart from Sandoz, Teva and more getting caught in CHMP and FDA’s crosshairs.
Strides Founder Back As MD, Asserts Confidence In US As Company Exits Parts Of Europe
Back as Strides managing director, founder Arun Kumar is confident of reversing a slide in profits via a recalibration strategy that saw the company exit Canada and a few European markets. Meanwhile, eyes are on the fallout of a CRO that serviced Strides apart from Sandoz, Teva and more getting caught in CHMP and FDA’s crosshairs